Maze Therapeutics (NASDAQ:MAZE) Stock Price Expected to Rise, HC Wainwright Analyst Says

Maze Therapeutics (NASDAQ:MAZE) had its price target raised by equities research analysts at HC Wainwright from $34.00 to $50.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 114.59% from the stock’s current price.

A number of other equities research analysts have also weighed in on the stock. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Wedbush assumed coverage on shares of Maze Therapeutics in a report on Tuesday, July 8th. They issued an “outperform” rating and a $17.00 price objective for the company. Finally, BTIG Research raised their price target on shares of Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $30.17.

Maze Therapeutics Stock Down 6.0%

NASDAQ:MAZE opened at $23.30 on Friday. The firm’s fifty day moving average is $15.28 and its 200-day moving average is $12.28. Maze Therapeutics has a 52 week low of $6.71 and a 52 week high of $25.50.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.77) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.02.

Institutional Investors Weigh In On Maze Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE grew its holdings in Maze Therapeutics by 33.6% in the second quarter. Bank of America Corp DE now owns 5,782 shares of the company’s stock worth $71,000 after purchasing an additional 1,455 shares during the period. CWM LLC bought a new position in Maze Therapeutics in the second quarter worth approximately $28,000. New York State Common Retirement Fund bought a new position in Maze Therapeutics in the first quarter worth approximately $25,000. Legal & General Group Plc raised its position in shares of Maze Therapeutics by 387.0% during the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after purchasing an additional 3,371 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in Maze Therapeutics by 452.5% during the second quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company’s stock valued at $57,000 after acquiring an additional 3,774 shares in the last quarter.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.